Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy
- 10 March 2009
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 135 (9) , 1239-1244
Abstract
Purpose Glioblastoma multiforme is the prototype of an angiogenic tumour. Under experimental conditions, anti-angiogenic therapy strategies lead to an increased invasion. Here we report on the pattern of tumour recurrence in glioblastoma patients treated with an anti-angiogenic chemotherapy. Patients and methods A total of 32 patients with glioblastoma multiforme and a residual tumour mass after operation were treated with a continuous low-dose chemotherapy with temozolomide and a COX-II inhibitor, a presumably anti-angiogenic therapy. Results While anti-tumour activity of this therapy regimen was excellent with a mean overall time to progression of 10.4 (±0.9) months and a mean overall survival of 17.8 (±1.5) months, an unusually high rate of distant recurrences was observed (62.5%). Conclusion Patients treated with an anti-angiogenic chemotherapy experience distant recurrences at a higher rate than reported for conventional therapies. This may reflect an anti-angiogenic therapy-induced activation of glioma invasion confirming similar recently published experimental results.Keywords
This publication has 42 references indexed in Scilit:
- Evaluation of Peritumoral Edema in the Delineation of Radiotherapy Clinical Target Volumes for GlioblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Efficacy of Different Regimens of Adjuvant Radiochemotherapy for Treatment of GlioblastomaTumori Journal, 2007
- Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survivalProceedings of the National Academy of Sciences, 2006
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Pattern of Recurrence following Local Chemotherapy with Biodegradable Carmustine (BCNU) Implants in Patients with GlioblastomaJournal of Neuro-Oncology, 2004
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogeneCancer Cell, 2003
- Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.2001
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJournal of Clinical Investigation, 2000
- Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.1992
- Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiformeJournal of Neurosurgery, 1983